| Identification | Back Directory | [Name]
5-Isoxazolecarboxamide, N-[2-methyl-5-[[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoyl]amino]phenyl]- | [CAS]
1135205-94-5 | [Synonyms]
AWL-II-38.3
5-Isoxazolecarboxamide, N-[2-methyl-5-[[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoyl]amino]phenyl]- | [Molecular Formula]
C23H18F3N5O3 | [MOL File]
1135205-94-5.mol | [Molecular Weight]
469.42 |
| Chemical Properties | Back Directory | [Boiling point ]
522.1±50.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 66.67 mg/mL (142.03 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.30±0.70(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Definition]
ChEBI: N-[2-methyl-5-[[[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-oxomethyl]amino]phenyl]-5-isoxazolecarboxamide is a member of benzamides. | [Biological Activity]
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf[1][2][1][2].
AWL-II-38.3 fits to LIMK2 and LIMK1 ATP-binding and substrate-binding pockets[2]. | [storage]
Store at -20°C | [References]
[1]. Yongmun Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70. [2]. Efrat Mashiach-Farkash, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39. |
|
|